The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2022 | The current status of lung cancer screening implementation
Matthijs Oudkerk, MD, PhD, University of Groningen, Groningen, Netherlands, talks on the Dutch-Belgian Randomized Lung Cancer Screening Trial (NELSON), and the National Lung Screening Trial (NLST) (NCT000473850) that demonstrated screening for lung cancer by low-dose computed tomography (LDCT) reduces lung cancer mortality. The U.S. Preventive Services Task Force subsequently revised the recommendation for the implementation of lung cancer screening, initiating lung cancer screening with LDCT in the U.S. A large European study involving multiple countries will commence in the coming year to investigate the optimal method for implementing lung cancer screening in Europe. This interview took place during the virtual European Lung Cancer Congress 2022.
